Stocks · News reference

Dermata Therapeutics Initiates Clinical Trial for Tome Clearing Treatment

2026-10-30 13:04:56 UTC

Dermata Therapeutics has enrolled the first participant in a clinical trial for its Tome Clearing Treatment, an acne product expected to launch in the first half of 2027.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DRMA

Source: fiscal.ai
Observed: 2026-10-30 13:04:56 UTC
Checked: 2026-10-30 13:05:20 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Fiscal.ai2026-11-05 14:05:36 UTC
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Brand
Dermata Therapeutics announced that its Tome skincare brand has received editorial coverage in several prominent beauty and lifestyle publications following its August 2026 commercial launch.
DRMA
SEC EDGAR2026-10-29 21:26:36 UTCSEC EDGAR
8-K filing — Dermata Therapeutics, Inc. (DRMA)
Filed: 2026-10-29 AccNo: 0001493152-26-049312 Size: 204 KB Item 8.01: Other Events
DRMA
Benzinga2026-10-15 17:29:42 UTCVandana Singh
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
DRMA
Benzinga2026-10-15 14:29:58 UTCBenzinga Newsdesk
Dermata Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.84%
DRMA
Benzinga2026-10-15 12:54:14 UTCBenzinga Newsdesk
Dermata Therapeutics shares are trading higher after the company reported study results showing skin appearance improvements with its Tome Foundational Treatment.
DRMA
Benzinga2026-10-15 12:10:26 UTCBenzinga Newsdesk
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic
DRMA

Dermata Therapeutics Initiates Clinical Trial for Tome Clearing Treatment

Connected Markets

Related Headlines

Dermata Therapeutics Highlights Media Recognition of Tome Skincare Brand

8-K filing — Dermata Therapeutics, Inc. (DRMA)

Why Is Dermata Therapeutics Stock Gaining Thursday?

Dermata Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.84%

Dermata Therapeutics shares are trading higher after the company reported study results showing skin appearance improvements with its Tome Foundational Treatment.

Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment